Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 11:07 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1849–1872 of 2,516 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Sequence Clear all

Conditions: Astigmatism
Interventions: Test Lens, Control Lens; Device
Lead sponsor: Johnson & Johnson Vision Care, Inc.; Industry
Eligibility: 18 Years to 39 Years
Enrollment: 134 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 12
States / cities: Jacksonville, Florida • Longwood, Florida • Maitland, Florida + 9 more

Conditions: Focal Epilepsy
Interventions: Lu AG06466, Placebo; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Essential Hypertension
Interventions: Bexagliflozin, Placebo; Drug
Lead sponsor: Theracos; Industry
Eligibility: 20 Years and older
Enrollment: 673 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 87
States / cities: Birmingham, Alabama • Foley, Alabama • Gulf Shores, Alabama + 76 more

Conditions: Healthy Volunteers
Interventions: PF-07976016 Formulation A, PF-07976016 Formulation B; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Intermittent Claudication
Interventions: Cilostazol 100 mg, PMR 200 mg; Drug
Lead sponsor: Genovate Biotechnology Co., Ltd.,; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Springfield, Missouri

Conditions: Healthy Volunteers
Interventions: Maribavir Commercial Tablet Formulation, Maribavir Pediatric Powder-for-oral Suspension Formulation, Rabeprazole; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Healthy
Interventions: LX4211; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2015
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Heart Failure, Heart Failure, Diastolic, Heart Failure With Preserved Ejection Fraction, Cardiac Failure, Heart Disease
Interventions: Beta blockers; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 65 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Tourette's Syndrome
Interventions: PF-03654746, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Manhasset, New York

Conditions: Apnea of Prematurity, Intermittent Hypoxemia, Bronchopulmonary Dysplasia of Newborn
Interventions: Chinstrap; Device
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 3 Days to 3 Months
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Pressure Ulcer
Interventions: Dabir Mattress Overlay System; Device
Lead sponsor: SerenaGroup, Inc.; Network
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Butler, Pennsylvania

Conditions: Alzheimer Disease, Mild Cognitive Impairment, Mild Dementia, Aging, Cognitive Change
Interventions: Retinal Imaging, Pupillometry, Contrast Sensitivity, Neuropsychological Evaluation, APOE genotyping, blood draw, Gait Assessment, Actigraphy; Other · Diagnostic Test · Genetic
Lead sponsor: University of Rhode Island; Other
Eligibility: 55 Years to 80 Years
Enrollment: 165 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2025
U.S. locations: 4
States / cities: Clearwater, Florida • St. Petersburg, Florida • Kingston, Rhode Island + 1 more

Conditions: Hamstring Contractures, Muscle Tightness
Interventions: Hypervolt, Body Tempering, Dry cupping, Static stretching; Device · Other
Lead sponsor: University of South Carolina; Other
Eligibility: 18 Years to 39 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Columbia, South Carolina

Conditions: Autism Spectrum Disorder
Interventions: Balovaptan, Esomeprazole; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Mountain Sickness
Interventions: Aminophylline, Methazolamide, Aminophylline and Methazolamide; Drug
Lead sponsor: Poudre Valley Health System; Other
Eligibility: 18 Years to 40 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Loveland, Colorado

Conditions: Oral Cancer
Interventions: Classification of Oral Microbiome Using 16S rRNA gene sequence-based approach, Classification of Oral Microbiome Using taxonomic approach; Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 40 Years to 92 Years
Enrollment: 560 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1992 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy Participants
Interventions: Elecoglipron Reference Formulation Dose A, Elecoglipron Test formulation 1 Dose A, Elecoglipron Reference Formulation Dose B, Elecoglipron Test formulation 1 Dose B, Elecoglipron Test formulation 2 Dose A, Elecoglipron Test formulation 2 Dose B; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 152 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 2
States / cities: Glendale, California • Brooklyn, Maryland

Conditions: Healthy
Interventions: Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC], Canagliflozin 50 mg, Canagliflozin 100 mg, Metformin Extended Release (XR); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Stress, Resilience, Quality of Life, Depressive Symptoms, Anxiety, Sleep, Physical Activity
Interventions: virtual reality; Device
Lead sponsor: City University of New York, School of Public Health; Other
Eligibility: 18 Years to 29 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Metastatic Colorectal Cancer, Stage II/III Colon Cancer
Interventions: blood collection for research (next generation sequencing [NGS]), blood collection for research (HLA typing), blood collection for research (circulating tumor DNA [ctDNA]); Procedure
Lead sponsor: Gritstone bio, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 6
States / cities: Miami, Florida • Tamarac, Florida • East Brunswick, New Jersey + 3 more

Conditions: Healthy
Interventions: Part A, Part B; Drug
Lead sponsor: Hutchison Medipharma Limited; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Cypress, California

Conditions: Healthy
Interventions: Canagliflozin/Probenecid; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 15 Years to 55 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Healthy Participants
Interventions: AZD5004, Rosuvastatin, Erythromycin, Atorvastatin, Simvastatin, Repaglinide; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: Healthy
Interventions: PF-06821497 Treatment A, PF-06821497 Treatment B, PF-06821497 Treatment C, PF-06821497 Treatment D, PF-06821497 Treatment E, PF-06821497 Treatment F; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: New Haven, Connecticut

Search by objective public record fields.

Evaluation of Delefilcon A and Senofilcon A Daily Disposable Toric Soft Contact Lenses Over One Week of Wear

A Study of Lu AG06466 in Participants With Treatment Resistant Focal Epilepsy

An Integrated Assessment of the Safety and Effectiveness of Bexagliflozin for the Management of Essential Hypertension

A Study to Learn How Different Forms of the Study Medicine Called PF-07976016 Are Taken Up Into the Blood in Healthy Adults

Bioequivalence Study of Once Daily PMR Compared to Twice Daily Cilostazol IR Tablets in Healthy Volunteers

A Study of Maribavir Pediatric Formulation in Healthy Adult Participants

Bioequivalence Study Between 400 mg LX4211 Tablets and 2 X 200 mg LX4211 Tablets

Impact of Beta-blockers on Physical Function in HFpEF

Study Evaluating The Safety And Efficacy Of PF-03654746 In Adult Subjects With Tourette's Syndrome

Strap To Reduce Apnea in Preterm Infants: A Randomized Crossover Trial

A Multicentre Prospective Study Evaluating an Off-loading Mattress Overlay System in Healing of Stage 3 Pressure Ulcers

Atlas of Retinal Imaging in Alzheimer's Study

Immediate and 24-hour Effects of HyperVolt, Body Tempering, and Cupping Compared to Stretching on Hamstring Flexibility

A Study to Investigate the Effect of Esomeprazole and the Effect of Food on the Pharmacokinetics of Balovaptan in Healthy Volunteers

Safety Evaluation of Aminophylline and Methazolamide

The Oral Microbiome and Upper Aerodigestive Squamous Cell Cancer

A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants

A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin XR Tablet Co-administered With Canagliflozin in Healthy Fed and Fasted Participants

Virtual Reality (VR) for Stress Management

A Screening Study Targeting Tumor-specific Antigens

Surufatinib DDI With a PPI and a CYP3A Inducer

A Study to Assess the Effects of Multiple-Dose Probenecid on the Multiple-Dose Pharmacokinetics of Canagliflozin in Healthy Volunteers

A Study to Investigate the Effect of AZD5004 on Rosuvastatin, Atorvastatin, Simvastatin, Repaglinide and the Effect of Erythromycin on AZD5004 in Healthy Participants

A Study to Understand the Effect of Tablet Formulation and Food on PF-06821497 in Healthy Adult Participants.